Please assess the completion status of the following clinical trial:

Trial Title: PUVA Maintenance Therapy in Mycosis Fungoides

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histopathologically documented MF clinical stage IA-IIB (see Table1) confirmed by current or previous diagnostic lesion biopsy~* A Karnofsky performance score \> 60~* No previous PUVA treatment~* Anti-ds-DNA (antinuclear antibodies) or anti-Ro/La antibodies: negative~* Acceptable organ function defined as follows:~SGOT (AST) and SGPT (ALT) \< 2.5 times the upper limit of normal for the institution~* Creatinine \< 2 times the upper limit of normal for the institution~* No evidence of severe cardiac insufficiency (NYHA grade III-IV)~* Women of child bearing potential must have a negative serum pregnancy test (ß-HCG) within seven (7) days prior to randomization~* Absence of any serious intercurrent illness or infection at time of entry into the study that could interfere with planned treatment~* Patients must be willing to accept limiting sun exposure on the day receiving PUVA treatment~* Written informed consent~Exclusion Criteria:~* Pregnancy and Lactation~* Photosensitive diseases such as lupus erythematosus or basal cell nevus syndrome~* Skin cancer syndromes such as xeroderma pigmentosum or basal cell nevus syndrome

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 82 Years
- Healthy Volunteers: f

Study Arms:
- PUVA maintenance treatment (Type: ACTIVE_COMPARATOR): Psoralen plus UVA (PUVA) treatment. The patients receive a standardized dose of oral 8-methoxypsoralen (Oxsoralen) 1 hour before UVA exposure
- No maintenance treatment (Type: NO_INTERVENTION): observation

Based on this trial design, predict the completion outcome and termination type (if applicable).